119 filings
Page 3 of 6
8-K
qmfkpct4we56u5 su6n0
23 Mar 23
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
7:35am
8-K
2jy pz6lychmr1fan
15 Mar 23
Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD
7:45am
8-K
7y9mhe02
10 Mar 23
Regulation FD Disclosure
4:35pm
424B5
02f 8yjaeuj
10 Mar 23
Prospectus supplement for primary offering
7:53am
8-K
hn0npuzk
10 Mar 23
Entry into a Material Definitive Agreement
7:51am
8-K
v1zrxe29 qp7
22 Feb 23
Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease
8:14am
8-K
3ifm2c1dswouw zoqn
13 Feb 23
Other Events
8:00am
EFFECT
t519yxpa0hml0tstd9j
4 Jan 23
Notice of effectiveness
12:15am
CORRESP
g6i64y nzt
29 Dec 22
Correspondence with SEC
12:00am
UPLOAD
2ml2i63 45kx
28 Dec 22
Letter from SEC
12:00am
8-K
8jovlyu7aa8
23 Dec 22
Entry into a Material Definitive Agreement
4:24pm
S-3
29oo87s1wgfx 4f
23 Dec 22
Shelf registration
4:16pm
8-K
t3axf 9ik2dy4zeerfi
16 Nov 22
Developing disease - modifying medicines for degenerative disorders November 2022
5:18pm
8-K
ns6khnki xvf3
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
424B4
gooq5 v8j6acs0sxul
14 Nov 22
Prospectus supplement with pricing info
6:02am
EFFECT
ej2ef558x qssjnl3zr
10 Nov 22
Notice of effectiveness
12:15am
CORRESP
k0nx 9f8k
7 Nov 22
Correspondence with SEC
12:00am
CORRESP
tvg1q17syngjo
7 Nov 22
Correspondence with SEC
12:00am